Summary

Hip replacement surgery (arthroplasty) is a highly successful treatment for patients with severe symptomatic arthritis of the hip joint. However, in younger more active patients, there is approximately a 50% failure rate at 25 years for traditional implants. The early results of Resurfacing Arthroplasty, a new technique where only part of the hip joint is replaced, suggest a 98% survival at five years; which is as good as any of the existing Total Hip Arthroplasties. However, in a recent review of the literature on Resurfacing Arthroplasty it was concluded that even though the short-term results on survival rate appear promising, some potential early disadvantages were identified, including risk of femoral neck fracture, avascular necrosis of the head of the femur and acetabular bone stock sacrifice.

This study is a pragmatic randomised controlled trial comparing total hip arthroplasty resurfacing arthroplasty. One-hundred and seventy-two patients will be randomised over an 18-20 month period and followed up at six weeks, three, six and twelve months post operatively. The principal outcomes will be measured at twelve months using validated outcome measures.

Chief Investigator: Matt Costa, Associate Professor of Trauma and Orthopaedic Surgery

Warwick Arthroplasty Trial Coordinator Dr Juul Achten
Telephone: 02476 968614
Email: J.Achten@warwick.ac.uk

Address: Warwick Arthroplasty Trial
Clinical Sciences Research Institute
Clifford Bridge Road
Coventry, CV2 2DX

Other Principal Unit Participants: Becky Hardcastle, Research Associate

Collaborating Investigators

Mr Udai Prakash, Mr Pedro Foguet, Professor Damian Griffin, Orthopaedic Consultants, University Hospitals Coventry and Warwickshire

Other Details

Status: Recruitment has started in Coventry

Funded by: National Institute of Health Research – Research for Patient Benefit.

Central Office for Research Ethics Committees approval reference number 07/Q2802/26